361 related articles for article (PubMed ID: 33995085)
21. PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer.
Roncolato F; Lindemann K; Willson ML; Martyn J; Mileshkin L
Cochrane Database Syst Rev; 2019 Oct; 10(10):CD012160. PubMed ID: 31588998
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative metastatic breast cancer: a network meta-analysis.
Leung JH; Leung HWC; Wang SY; Huang SS; Chan ALF
Expert Opin Drug Saf; 2021 Aug; 20(8):949-957. PubMed ID: 34047239
[TBL] [Abstract][Full Text] [Related]
23. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC; Oliveira M; Howell SJ; Dalenc F; Cortes J; Gomez Moreno HL; Hu X; Jhaveri K; Krivorotko P; Loibl S; Morales Murillo S; Okera M; Park YH; Sohn J; Toi M; Tokunaga E; Yousef S; Zhukova L; de Bruin EC; Grinsted L; Schiavon G; Foxley A; Rugo HS;
N Engl J Med; 2023 Jun; 388(22):2058-2070. PubMed ID: 37256976
[TBL] [Abstract][Full Text] [Related]
24. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
Burris HA
Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
[TBL] [Abstract][Full Text] [Related]
25. A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach.
Gul A; Leyland-Jones B; Dey N; De P
Am J Cancer Res; 2018; 8(12):2359-2376. PubMed ID: 30662797
[TBL] [Abstract][Full Text] [Related]
26. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
27. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
Ciruelos Gil EM
Cancer Treat Rev; 2014 Aug; 40(7):862-71. PubMed ID: 24774538
[TBL] [Abstract][Full Text] [Related]
28. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Kim SB; Dent R; Im SA; Espié M; Blau S; Tan AR; Isakoff SJ; Oliveira M; Saura C; Wongchenko MJ; Kapp AV; Chan WY; Singel SM; Maslyar DJ; Baselga J;
Lancet Oncol; 2017 Oct; 18(10):1360-1372. PubMed ID: 28800861
[TBL] [Abstract][Full Text] [Related]
29. [Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer].
; ; ;
Zhonghua Zhong Liu Za Zhi; 2022 Jul; 44(7):673-692. PubMed ID: 35880333
[TBL] [Abstract][Full Text] [Related]
30. PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative.
Ascione L; Zagami P; Nicolò E; Crimini E; Curigliano G; Criscitiello C
J Pers Med; 2022 Oct; 12(11):. PubMed ID: 36579519
[TBL] [Abstract][Full Text] [Related]
31. Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells.
Morgillo F; Della Corte CM; Diana A; Mauro CD; Ciaramella V; Barra G; Belli V; Franzese E; Bianco R; Maiello E; de Vita F; Ciardiello F; Orditura M
Oncotarget; 2017 Sep; 8(44):76479-76491. PubMed ID: 29100327
[TBL] [Abstract][Full Text] [Related]
32. CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials.
Xu H; Wang Y; Han Y; Wu Y; Wang J; Xu B
Front Oncol; 2022; 12():956464. PubMed ID: 36091147
[TBL] [Abstract][Full Text] [Related]
33. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients.
Ghayad SE; Cohen PA
Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):29-57. PubMed ID: 19751211
[TBL] [Abstract][Full Text] [Related]
34. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA
Clin Breast Cancer; 2020 Apr; 20(2):89-97. PubMed ID: 31932237
[TBL] [Abstract][Full Text] [Related]
35. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
O'Brien NA; McDermott MSJ; Conklin D; Luo T; Ayala R; Salgar S; Chau K; DiTomaso E; Babbar N; Su F; Gaither A; Hurvitz SA; Linnartz R; Rose K; Hirawat S; Slamon DJ
Breast Cancer Res; 2020 Aug; 22(1):89. PubMed ID: 32795346
[TBL] [Abstract][Full Text] [Related]
36. Everolimus: targeted therapy on the horizon for the treatment of breast cancer.
Barnett CM
Pharmacotherapy; 2012 Apr; 32(4):383-96. PubMed ID: 22461124
[TBL] [Abstract][Full Text] [Related]
37. PI3K Inhibitors in Breast Cancer Therapy.
Ellis H; Ma CX
Curr Oncol Rep; 2019 Dec; 21(12):110. PubMed ID: 31828441
[TBL] [Abstract][Full Text] [Related]
38. Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies.
Sharifi MN; Anandan A; Grogan P; O'Regan RM
Cancer; 2020 Aug; 126(15):3400-3416. PubMed ID: 32426848
[TBL] [Abstract][Full Text] [Related]
39. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.
Liu ST; Hui G; Mathis C; Chamie K; Pantuck AJ; Drakaki A
Clin Genitourin Cancer; 2018 Apr; 16(2):e269-e276. PubMed ID: 29199023
[TBL] [Abstract][Full Text] [Related]
40. Targeting Akt in cancer for precision therapy.
Hua H; Zhang H; Chen J; Wang J; Liu J; Jiang Y
J Hematol Oncol; 2021 Aug; 14(1):128. PubMed ID: 34419139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
